Presisdent Marc Hedrick presents as part of the Cardiac Cell Therapy at the 1st Annual Regen Med Investor Day

1. 1st Annual Regen Med Investor Day
Clinical Outlooks in Cardiovascular Disease
Marc Hedrick, MD
Cytori Therapeutics (NASDAQ:CYTX)
President
April 17, 2013

2. Safe Harbor Statement
This presentation contains certain ‘forward-looking statements’ about Cytori Therapeutics, Inc. All
statements, other than statements of historical fact, that address activities, events or developments that we
intend, expect, project, believe or anticipate will or may occur in the future are forward-looking statements.
Such statements are based upon certain assumptions and assessments made by our management in light of
their experience and their perception of historical trends, current conditions, expected future developments
and other factors they believe to be appropriate.
The forward-looking statements included in this presentation involve known and unknown risks that relate to
Cytori’s future events or future financial performance and the actual results could differ materially from those
discussed in this presentation. Risks and uncertainties that may cause Cytori's actual results to differ
materially from those discussed in the presentation can be found in the "Risk Factors" section of Cytori’s
Form 10-K, Forms 10-Q and other filings with the United States Securities and Exchange Commission. We
would advise reading our most recent annual report on Form 10-K and quarterly report on Form 10-Q filed
with the United States Securities and Exchange Commission for a more detailed description of these risks.
The forward-looking statements contained in this presentation represent Cytori’s estimates and assumptions
only as of the date of this presentation and Cytori undertakes no duty or obligation to update or revise
publicly any forward-looking statements contained in this presentation as a result of new information, future
events or changes in Cytori’s expectations.

3. Cytori Cell Therapy: Unique Attributes
Proprietary formulation of ADRCs
•Autologous
•Mixed cell population
•Various mechanisms
•Patented process
•Virtually ‘off the shelf’

4. Cytori Cell Therapy: Heterogeneity
Vascular Mechanisms of Action
Smooth Tissue
Muscle Cells Macrophages
9% 23%
• Paracrine (local GF
Endothelial
delivery)
Cells
7% • Differentiation
• Inflammatory modulation
• Angiogenesis
• Wound healing
White Blood
CD34+/ Cells
CD31- Stem Cells
2% 22%
37%

5. Cytori Cell Therapy: Cardiovascular Trials
EU Pilot US Pilot Pivotal
Complete In Progress
Acute MI APOLLO ADVANCE
N = 14, Europe N = 216, Europe
Complete In Progress Preliminary
Chronic
Myocardial ATHENA II
PRECISE ATHENA
Ischemia N=TBD,
N = 27, Europe N = 45, USA
International
Summary from European Pilot Trials
• AMI- safe and trend toward reduction in infarct size, favorable remodeling
• HF & CMI- safe & statistically significant stabilization in Max VO2

6. Cytori Cell Therapy: Economics
Procedures / Est. Consumable Est. Consumable
Est. Revenue
Year ASP Gross Profit
100,000 $10,000 $1 Billion $800 + Million
System:
• Low six figure ASP (current generation)
• Next-generation system COGS~ $10,000, flexible model
Per-procedure consumable:
• $8,000-$12,000 for vascular indications
• >80% GM